Related Experiment Video
Updated: May 17, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.4K
Isorhapontigenin Inhibits Cell Growth, Angiogenesis, Migration, and Invasion of Non-Small-Cell Lung Cancer Cells
Zhuo Zhang1, Jingxia Li1, Daneah Willis1
1Division of Environmental Medicine, Department of Medicine, New York University Grossman School of Medicine, 341 E 25th Street, New York, NY 10010, USA.
International Journal of Molecular Sciences
|May 14, 2025
Summary
Isorhapontigenin (ISO), a dietary stilbene, shows promise in treating lung cancer by inhibiting tumor growth, spread, and blood vessel formation. It effectively reduces Neural precursor cell expressed developmentally downregulated 9 (NEDD9) and hypoxia-inducible factor-1α (HIF-1α) levels.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lung cancer remains a leading cause of cancer mortality despite available treatments.
- There is a critical need for novel therapeutic agents with improved safety profiles.
- Phytochemicals, like Isorhapontigenin (ISO), are being investigated as potential anti-cancer drugs.
Purpose of the Study:
- To investigate the anti-cancer effects of Isorhapontigenin (ISO) on human lung cancer.
- To explore the role of Neural precursor cell expressed developmentally downregulated 9 (NEDD9) in lung cancer progression.
- To determine the molecular mechanisms underlying ISO's therapeutic potential.
Main Methods:
- In vitro studies using human lung cancer cell lines.
- Analysis of NEDD9 protein levels in lung cancer tissues.
- Assessment of ISO's impact on cell growth, angiogenesis, invasion, and migration.
- Evaluation of ISO's effect on key molecular targets including NEDD9, HIF-1α, and β-Catenin.
Main Results:
- ISO treatment significantly inhibited human lung cancer cell growth, angiogenesis, invasion, and migration.
- NEDD9 was found to be upregulated in lung adenocarcinomas and squamous-cell carcinomas and promotes cancer cell invasion.
- ISO treatment decreased NEDD9 protein levels, reduced angiogenesis, and lowered HIF-1α and β-Catenin activation.
Conclusions:
- Isorhapontigenin (ISO) demonstrates potent anti-cancer properties against human lung cancer.
- Downregulation of NEDD9 by ISO is a key mechanism contributing to its therapeutic effects.
- ISO represents a promising therapeutic agent for lung cancer treatment.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:35Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K